Downloads
Poster: Stabilization Of Cell-Free RNA In Plasma For Noninvasive Diagnosis And Prognosis
By M. R. Fernando, S. Norton and W. L. Ryan, Streck, Inc.
The discovery of the presence of cell-free nucleic acids in blood (1) and subsequent demonstrations that cell-free nucleic acids were elevated in certain disease conditions (2) suggested the usefulness of cell-free nucleic acids in non-invasive diagnosis and prognosis. The clinical utility of cell-free mRNA in blood as diagnostic and prognostic markers was first demonstrated in cancer patients (3). The presence of fetal cell-free mRNA in maternal blood was initially reported in 2000 by Poon et al. (4). Following this discovery many other clinically important fetal/placental cell-free mRNA molecules were found to be present in maternal blood. These discoveries have presented us with opportunities to develop non-invasive diagnostic and prognostic tools based on cell-free RNA. Due to its labile nature, there are inherent disadvantages of using cell-free mRNA in blood as biomarkers. Since plasma is rich in nucleases, cell-free mRNA tends to degrade during sample handling and processing. Another disadvantage is the release of non-target background RNA from blood cells during sample processing and storage. This kind of background increase hampers the detection of rare mRNA targets.
The content you requested is only available to registered users of Bioresearch Online. By registering now, you'll get access to this piece of content and thousands of additional articles and product reviews across our entire network of sites.
